The results of our study are concordant with previously reported analyses which show a high prevalence of BRCA1/2 mutations among ovarian cancer patients with dominant founder/recurrent population-specific mutations located in BRCA1. This evidence concerns the gene BRCA1 and ovarian carcinoma.